Desmopressin Sandoz: Uses, Dosage & Side Effects
Synthetic vasopressin analogue for diabetes insipidus, bedwetting, and nocturia
Quick Facts About Desmopressin Sandoz
Key Takeaways About Desmopressin Sandoz
- Restricting fluid intake is critical: You must limit fluids from 1 hour before to 8 hours after taking desmopressin to prevent dangerous water intoxication and low sodium levels
- Treats three main conditions: Central diabetes insipidus, bedwetting in children 5 years and older, and excessive nighttime urination in adults
- Regular blood tests needed: Sodium levels should be monitored before starting and during treatment, especially in older patients and children
- Multiple drug interactions: NSAIDs, antidepressants (SSRIs, tricyclics), and carbamazepine can increase the risk of hyponatraemia when combined with desmopressin
- Not for everyone over 65: Use for bedwetting or nocturia is generally not recommended in patients over 65 due to increased risk of hyponatraemia
What Is Desmopressin Sandoz and What Is It Used For?
Desmopressin Sandoz contains the active substance desmopressin acetate, a synthetic version of the body's natural antidiuretic hormone (vasopressin/ADH). It reduces urine production by acting on the kidneys, making it effective for conditions involving excessive or uncontrolled urination including diabetes insipidus, bedwetting, and nocturia.
Desmopressin is a modified synthetic analogue of arginine vasopressin (AVP), the natural hormone produced by the posterior pituitary gland that regulates water balance in the body. The chemical modification gives desmopressin a longer duration of action and greatly reduced vasopressor (blood pressure-raising) effect compared to natural vasopressin. This makes it safer and more practical for clinical use.
When the body produces insufficient vasopressin, or when the kidneys do not respond adequately to the hormone, excessive urine production occurs. Desmopressin compensates for this deficiency by binding to V2 receptors in the renal collecting ducts, increasing water reabsorption and thereby concentrating the urine and reducing its volume. The medication has a selective antidiuretic action with minimal effect on blood pressure at therapeutic doses.
Desmopressin Sandoz is manufactured by Sandoz, a major global generics pharmaceutical company. The medication is available in several formulations to suit different patient needs and clinical situations. It is bioequivalent to the original branded product and undergoes the same rigorous quality control standards required by European and international regulatory authorities.
Approved Indications
Desmopressin Sandoz is approved for the following conditions:
- Central diabetes insipidus: A condition where the pituitary gland does not produce enough vasopressin, resulting in excessive urination (polyuria) and extreme thirst (polydipsia). This can be caused by head trauma, surgery, tumours, or genetic conditions.
- Primary nocturnal enuresis (bedwetting): For children aged 5 years and older who have not responded to behavioural interventions such as alarm therapy. Desmopressin reduces nighttime urine production, helping children stay dry through the night.
- Nocturia in adults: Excessive nighttime urination that disrupts sleep. Desmopressin is used when nocturia is caused by nocturnal polyuria (overproduction of urine at night) and other causes have been excluded.
How Desmopressin Works (Mechanism of Action)
Desmopressin acts primarily on the V2 vasopressin receptors located in the basolateral membrane of the principal cells of the renal collecting duct. When desmopressin binds to these receptors, it triggers a signalling cascade involving cyclic AMP (cAMP) that causes aquaporin-2 water channels to be inserted into the apical membrane of these cells. This dramatically increases the water permeability of the collecting duct, allowing water to be reabsorbed from the urine back into the bloodstream.
Unlike natural vasopressin, desmopressin has very low affinity for V1a receptors (found on blood vessel smooth muscle) and V1b receptors (found in the anterior pituitary). This means it causes minimal vasoconstriction and does not significantly affect blood pressure at normal therapeutic doses. The modification at position 1 (deamination) increases antidiuretic potency and prolongs duration of action, while the D-arginine substitution at position 8 virtually eliminates the vasopressor effect.
After oral administration, desmopressin has a bioavailability of approximately 0.1-0.2%. Despite this low bioavailability, the oral formulations are clinically effective when dosed appropriately. Sublingual (melt) tablets have approximately 60% higher bioavailability than standard oral tablets, which is why their doses are expressed in micrograms rather than milligrams. Peak plasma concentrations are reached within 1-2 hours, and the antidiuretic effect typically lasts 6-12 hours.
What Should You Know Before Taking Desmopressin Sandoz?
Before starting desmopressin, you must tell your doctor about any heart, kidney, or bladder conditions, medications you take, and your typical fluid intake. Desmopressin is contraindicated in habitual polydipsia, cardiac insufficiency requiring diuretic treatment, and moderate-to-severe renal insufficiency. Baseline sodium levels must be checked before starting treatment.
Desmopressin is a potent medication that affects the body's water balance. While it is generally well tolerated when used correctly, there are important safety considerations that must be discussed with your prescribing physician before starting treatment. The risk of serious adverse effects, particularly hyponatraemia (dangerously low blood sodium), can be minimised by following your doctor's instructions carefully regarding fluid restriction and monitoring.
Contraindications
You must not take Desmopressin Sandoz if any of the following apply to you:
- Habitual or psychogenic polydipsia: If you habitually drink excessive amounts of water (more than 40 ml per kilogram body weight per 24 hours), desmopressin can cause dangerous water retention
- Known or suspected cardiac insufficiency and other conditions requiring treatment with diuretic medicines
- Moderate to severe renal insufficiency (creatinine clearance below 50 ml/min)
- Known hyponatraemia (low blood sodium levels)
- Syndrome of inappropriate ADH secretion (SIADH)
- Hypersensitivity to desmopressin acetate or any of the excipients
Warnings and Precautions
Special care is needed when using desmopressin in the following situations:
The most important safety consideration with desmopressin is the risk of hyponatraemia and water intoxication. When desmopressin reduces urine output, any excess fluid you consume will be retained in the body, diluting blood sodium to potentially dangerous levels. Symptoms of hyponatraemia include headache, nausea, vomiting, weight gain, confusion, and in severe cases seizures, coma, or death.
You must restrict fluid intake from 1 hour before taking desmopressin until at least 8 hours after. Do not drink more than 200 ml (one glass) during this period unless specifically advised otherwise by your doctor.
- Elderly patients (over 65 years): Are at increased risk of hyponatraemia. Desmopressin for nocturia or enuresis is generally not recommended in this age group. If used for diabetes insipidus, careful sodium monitoring is essential.
- Children: Must be carefully supervised regarding fluid intake. Parents should be thoroughly instructed about fluid restriction.
- Conditions affecting water balance: Cystic fibrosis, fever, gastroenteritis, or vigorous exercise can alter fluid and electrolyte balance, increasing the risk of hyponatraemia.
- Bladder dysfunction: Patients with conditions causing urinary obstruction, such as benign prostatic hyperplasia, should be evaluated before starting treatment.
- Ongoing illness: Treatment should be temporarily interrupted during acute intercurrent illness with fluid or electrolyte imbalance (such as fever, vomiting, or diarrhoea).
Pregnancy and Breastfeeding
Limited data from clinical experience suggests that desmopressin does not appear to cause harm during pregnancy. Studies in pregnant women with diabetes insipidus have not shown increased risks of malformations or adverse pregnancy outcomes. However, desmopressin should only be used during pregnancy when the benefit clearly outweighs any potential risk, and under close medical supervision.
Small amounts of desmopressin may pass into breast milk, but studies have shown that the amounts are too small to have any clinically significant effect on the nursing infant. The low oral bioavailability of desmopressin means that even if small amounts are ingested by the infant through breast milk, absorption would be negligible. Your doctor will advise whether you can continue breastfeeding while taking desmopressin.
Your doctor should check your blood sodium level before starting desmopressin, and recheck it after 3 days and after 1 week, then at regular intervals throughout treatment. For bedwetting in children, treatment should be reviewed after 3 months with a 1-week treatment break to assess whether the condition has resolved.
How Does Desmopressin Sandoz Interact with Other Drugs?
Several medications can increase the antidiuretic effect of desmopressin or independently lower sodium levels, raising the risk of hyponatraemia. The most important interactions are with NSAIDs (ibuprofen, naproxen), SSRI antidepressants, tricyclic antidepressants, carbamazepine, and chlorpromazine. Always inform your doctor of all medications you are taking.
Drug interactions with desmopressin are clinically significant because they can increase the risk of the medication's most serious adverse effect: hyponatraemia (low blood sodium). Any drug that either enhances the antidiuretic effect of desmopressin or independently causes water retention or sodium loss can potentially lead to dangerous hyponatraemia when combined with desmopressin. Your doctor needs to be aware of all prescription and over-the-counter medicines, herbal products, and supplements you are taking.
Major Interactions
The following drug classes are known to increase the risk of hyponatraemia when combined with desmopressin and require careful monitoring or dose adjustment:
| Drug / Class | Examples | Interaction Mechanism | Clinical Significance |
|---|---|---|---|
| NSAIDs | Ibuprofen, naproxen, diclofenac, indomethacin | Enhance antidiuretic effect by inhibiting renal prostaglandin synthesis, reducing renal water excretion | High risk – may cause significant water retention and hyponatraemia |
| SSRIs | Sertraline, fluoxetine, paroxetine, citalopram | Can independently cause SIADH and hyponatraemia, compounding the risk | High risk – additive hyponatraemia risk, particularly in elderly |
| Tricyclic antidepressants | Amitriptyline, imipramine, nortriptyline, clomipramine | Enhance antidiuretic effect and may independently cause hyponatraemia | High risk – particularly relevant as imipramine was historically used for enuresis |
| Carbamazepine | Tegretol, Carbatrol | Enhances antidiuretic effect of desmopressin and can cause SIADH independently | High risk – both drugs independently lower sodium |
| Chlorpromazine | Thorazine, Largactil | Enhances antidiuretic effect of desmopressin | Moderate risk – monitor sodium closely |
Minor Interactions
The following interactions are of lesser clinical significance but should still be noted:
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Loperamide (Imodium) | May increase desmopressin plasma levels by up to 3-fold | Use with caution; increased fluid restriction may be needed |
| Thiazide diuretics | Can independently cause hyponatraemia, additive risk | Monitor sodium levels; combination generally not recommended |
| Oxybutynin | Sometimes combined with desmopressin for enuresis; may enhance effect | Close monitoring of fluid balance and sodium recommended |
| Lamotrigine | Theoretical risk of enhanced antidiuretic effect | Monitor if used concurrently |
Ibuprofen and naproxen (NSAIDs) are available over-the-counter in many countries and can significantly increase the risk of hyponatraemia with desmopressin. If you need pain relief while taking desmopressin, paracetamol (acetaminophen) is generally considered safer as it does not interact with desmopressin's antidiuretic effect. Always consult your doctor or pharmacist before taking any new medication.
What Is the Correct Dosage of Desmopressin Sandoz?
Dosage varies by indication and formulation. For diabetes insipidus, typical oral doses are 0.1–0.2 mg two to three times daily. For bedwetting, the starting dose is usually 0.2 mg at bedtime. For nocturia, sublingual melt tablets of 60 mcg (women) or 120 mcg (men) are taken at bedtime. Your doctor will individualise your dose based on your response.
Desmopressin dosing is highly individualised and depends on the condition being treated, the formulation used, and the patient's response. The dose that controls symptoms while maintaining safe sodium levels is determined through careful titration. It is essential to follow your doctor's specific dosing instructions, as the doses and units differ between tablet formulations and melt (sublingual lyophilisate) formulations.
Tablet and melt (sublingual) formulations are not interchangeable on a microgram-to-microgram basis. The melt tablet has approximately 60% higher bioavailability than the standard oral tablet. A 0.2 mg (200 mcg) standard tablet is approximately equivalent to a 120 mcg melt tablet. Always follow your specific prescription exactly.
Adults
Central Diabetes Insipidus (Adults)
Oral tablets: Starting dose 0.1 mg (100 mcg) three times daily. Adjusted based on urine output and fluid balance. Usual maintenance dose: 0.1–0.2 mg two to three times daily. Total daily dose typically ranges from 0.2 mg to 1.2 mg.
Sublingual melt tablets: Starting dose 60 mcg three times daily. Maintenance: 60–120 mcg two to three times daily.
Nasal spray: 10–40 mcg daily, as a single dose or divided into two to three doses.
Nocturia (Adults under 65 years)
Sublingual melt tablets: Women: 25 mcg or 50 mcg at bedtime (some formulations start at 60 mcg). Men: 50 mcg or 100 mcg at bedtime (some formulations start at 120 mcg). Dose may be increased after 1 week if insufficient response, up to a maximum depending on the specific product.
Oral tablets: Starting dose 0.1 mg at bedtime. May be increased to 0.2 mg or 0.4 mg if needed.
Note: Treatment should be started at the lowest effective dose. Sodium should be checked at day 3, day 7, and 1 month after starting or changing dose.
Children
Primary Nocturnal Enuresis (Children 5 years and older)
Oral tablets: Starting dose 0.2 mg at bedtime. If inadequate response after 1–2 weeks, dose may be increased to 0.4 mg at bedtime.
Sublingual melt tablets: Starting dose 120 mcg at bedtime. May be increased to 240 mcg if needed.
Duration: Treatment is usually continued for 3 months, then interrupted for at least 1 week to assess whether the condition has resolved. Treatment can be restarted if bedwetting recurs.
Fluid restriction: The child must limit fluid intake from 1 hour before to 8 hours after the dose. Ensure the child empties their bladder before bed.
Central Diabetes Insipidus (Children)
Oral tablets: Starting dose 0.05–0.1 mg (50–100 mcg) twice daily. Dose is individually adjusted based on urine output and plasma osmolality. Usual maintenance: 0.1–0.8 mg daily in divided doses.
Nasal spray: 5–20 mcg daily, as a single dose or divided.
Elderly
Patients over 65 years of age are at significantly increased risk of hyponatraemia. Desmopressin for nocturia is generally not recommended in this age group. If it must be used for diabetes insipidus in elderly patients, the lowest effective dose should be chosen and sodium levels monitored frequently (before treatment, after 3 days, after 1 week, then monthly).
Missed Dose
If you miss a dose, take it as soon as you remember – but only if it is not close to the time for your next dose. Never take a double dose to make up for a missed one. For bedwetting, if you miss the evening dose and it is already late at night, skip that dose and take the next dose the following evening. For diabetes insipidus, contact your doctor if you miss multiple doses, as urine output may increase significantly.
Overdose
An overdose of desmopressin increases the risk of severe hyponatraemia and water intoxication. Symptoms may include headache, nausea, vomiting, excessive weight gain, lethargy, confusion, muscle cramps, and in severe cases seizures and loss of consciousness.
If you suspect an overdose, stop taking desmopressin immediately and restrict all fluid intake. Seek urgent medical attention. Treatment of overdose-induced hyponatraemia may include careful fluid restriction, and in severe cases, administration of intravenous hypertonic saline under close monitoring. Rapid correction of sodium must be avoided as it can cause osmotic demyelination syndrome.
What Are the Side Effects of Desmopressin Sandoz?
The most common side effects include headache, nausea, abdominal pain, and nasal congestion (with nasal formulations). The most serious side effect is hyponatraemia (low blood sodium), which can occur if fluid intake is not properly restricted. Most patients tolerate desmopressin well when fluid restriction guidelines are followed carefully.
Like all medicines, Desmopressin Sandoz can cause side effects, although not everybody gets them. The likelihood and severity of side effects depend on the dose, formulation, and individual patient factors. The most clinically significant adverse effect is hyponatraemia, which is preventable through proper fluid restriction and monitoring. Most other side effects are mild and transient.
The side effects are listed below by frequency, based on data from clinical trials and post-marketing surveillance:
Very Common (affects more than 1 in 10 people)
- Headache
Common (affects 1 to 10 in 100 people)
- Nausea
- Abdominal pain
- Dizziness
- Dry mouth
- Hyponatraemia (low sodium, with or without symptoms)
- Nasal congestion, rhinitis, epistaxis (nosebleed) – with nasal formulations
- Peripheral oedema (mild swelling)
Uncommon (affects 1 to 10 in 1,000 people)
- Insomnia or sleep disturbances
- Fatigue
- Vomiting
- Diarrhoea
- Weight gain
- Muscle cramps
- Increased blood pressure (transient)
Rare (affects fewer than 1 in 1,000 people)
- Severe hyponatraemia with seizures or coma
- Allergic reactions (rash, urticaria, anaphylaxis)
- Confusion or altered mental status
- Visual disturbances
- Emotional changes in children
Contact your doctor or emergency services immediately if you experience any of the following while taking desmopressin:
- Persistent or severe headache
- Nausea, vomiting, or unexplained weight gain
- Confusion, drowsiness, or unusual tiredness
- Muscle cramps or weakness
- Seizures (convulsions)
- Signs of allergic reaction: rash, swelling of face/lips/tongue, difficulty breathing
These symptoms may indicate hyponatraemia or an allergic reaction. Stop taking desmopressin and restrict all fluid intake until you receive medical advice.
If you experience any side effects not listed here, or if any side effect becomes severe, please report it to your doctor, pharmacist, or your national pharmacovigilance authority. You can also report side effects directly to help monitor medication safety.
How Should You Store Desmopressin Sandoz?
Store Desmopressin Sandoz tablets below 25°C (77°F) in the original packaging to protect from moisture. Melt (sublingual) tablets should be kept in the blister pack until ready to use. Nasal spray should be stored upright at 2–8°C (refrigerated) before opening, then at room temperature for up to 4 weeks after first use.
Proper storage of desmopressin is important to ensure the medication remains effective throughout its shelf life. Different formulations have different storage requirements, so always check the packaging for specific instructions.
Storage Guidelines by Formulation
- Oral tablets: Store below 25°C in a dry place. Keep in the original packaging to protect from moisture and light. Do not remove tablets from the blister pack until you are ready to take them.
- Sublingual melt tablets: Store below 25°C. These tablets are particularly sensitive to moisture. Keep in the sealed blister pack until immediately before use. Handle with dry hands and place directly on the tongue.
- Nasal spray: Before opening, store in the refrigerator (2–8°C). After first use, store at room temperature (below 25°C) for up to 4 weeks. Keep the bottle upright. Discard 4 weeks after opening.
- Solution for injection: Store in a refrigerator (2–8°C). Do not freeze. Protect from light.
Keep all medicines out of the sight and reach of children. Do not use Desmopressin Sandoz after the expiry date printed on the packaging. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.
What Does Desmopressin Sandoz Contain?
The active substance is desmopressin acetate. Each tablet contains either 0.1 mg or 0.2 mg of desmopressin acetate. Melt tablets contain 60, 120, or 240 micrograms. The inactive ingredients (excipients) vary by formulation but include lactose monohydrate, potato starch, povidone, and magnesium stearate in standard tablets.
Active Substance
The active ingredient in all Desmopressin Sandoz formulations is desmopressin acetate (also known as 1-deamino-8-D-arginine vasopressin acetate or DDAVP). Desmopressin is a synthetic analogue of the naturally occurring human hormone arginine vasopressin (antidiuretic hormone). Its molecular formula is C46H64N14O12S2 and it has a molecular weight of approximately 1069 Da (as the free base).
Inactive Ingredients (Excipients)
The specific excipients depend on the formulation:
- Standard oral tablets (0.1 mg, 0.2 mg): Lactose monohydrate, potato starch, povidone K30, magnesium stearate. The tablets may also contain stearic acid and colloidal silicon dioxide.
- Sublingual melt tablets (60, 120, 240 mcg): Gelatin, mannitol, citric acid anhydrous. These are formulated to disintegrate rapidly on the tongue without water.
- Nasal spray solution: Sodium chloride, hydrochloric acid (for pH adjustment), purified water. The solution may also contain chlorobutanol as a preservative.
The standard oral tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The sublingual melt tablets are lactose-free and may be a suitable alternative for patients with lactose intolerance.
Frequently Asked Questions About Desmopressin Sandoz
Medical References & Sources
All medical information is based on peer-reviewed sources and international clinical guidelines. Evidence level: 1A (systematic reviews and randomised controlled trials).
- European Medicines Agency (EMA). Desmopressin – Summary of Product Characteristics. EMA Product Information Database. Accessed 2026.
- British National Formulary (BNF). Desmopressin. NICE Evidence Services. Updated 2025.
- Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Current Drug Safety. 2007;2(3):232–238.
- Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. New England Journal of Medicine. 1989;321(8):492–496.
- Glazener CMA, Evans JHC. Desmopressin for nocturnal enuresis in children. Cochrane Database of Systematic Reviews. 2002;(3):CD002112.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourology and Urodynamics. 1999;18(6):559–565.
- U.S. Food and Drug Administration (FDA). DDAVP (desmopressin acetate) – Prescribing Information. FDA Drug Label Database. Accessed 2026.
- Robson WLM, Leung AKC, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. Journal of Urology. 2007;178(1):24–30.
- Juul KV, Bichet DG, Nielsen S, Norgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. American Journal of Physiology – Renal Physiology. 2014;306(9):F931–F940.
About the iMedic Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians with expertise in endocrinology, nephrology, paediatrics, and clinical pharmacology.
Medical Qualifications
- Board-certified specialist physicians
- Clinical experience in endocrinology and nephrology
- Published research in peer-reviewed journals
Review Process
- Evidence-based content following GRADE framework
- Multiple peer review before publication
- Regular updates based on new evidence
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer review before publication. No commercial funding influences our content.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in endocrinology, nephrology, pharmacology, and paediatrics.